We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Cochlear Limited is a medical devices business based in Australia. Cochlear shares (COH) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Cochlear has a trailing 12-month revenue of around $1.5 billion. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $174.6841 - $256.2311 |
|---|---|
| 50-day moving average | $225.9008 |
| 200-day moving average | $231.8742 |
| Target price | $223.68 |
| PE ratio | 44.846 |
| Dividend yield | $2.55 (1.16%) |
| Earnings per share (TTM) | $4.967 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$222.36
| 1 week (2021-10-19) | 1.40% |
|---|---|
| 1 month (2021-09-24) | -1.49% |
| 3 months (2021-07-26) | -10.31% |
| 6 months (2021-04-26) | -0.63% |
| 1 year (2020-10-26) | -2.19% |
|---|---|
| 2 years (2019-10-25) | 7.20% |
| 3 years (2018-10-26) | 28.12% |
| 5 years (2016-10-26) | 74.81% |
Valuing Cochlear stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cochlear's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cochlear's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 45x. In other words, Cochlear shares trade at around 45x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Cochlear's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $385.7 million (£0.0 million).
The EBITDA is a measure of a Cochlear's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.5 billion |
|---|---|
| Operating margin TTM | 23% |
| Gross profit TTM | $1.1 billion |
| Return on assets TTM | 8.59% |
| Return on equity TTM | 21.04% |
| Profit margin | 21.8% |
| Book value | 25.884 |
| Market capitalisation | $14.7 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Cochlear.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 24.39
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Cochlear's overall score of 24.39 (as at 12/31/2018) is nothing to write home about – landing it in it in the 45th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Cochlear is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.73/100
Cochlear's environmental score of 3.73 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Cochlear is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 14.34/100
Cochlear's social score of 14.34 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Cochlear is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 10.32/100
Cochlear's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Cochlear is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Cochlear scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Cochlear has, for the most part, managed to keep its nose clean.
Cochlear Limited was last rated for ESG on: 2019-01-01.
| Total ESG score | 24.39 |
|---|---|
| Total ESG percentile | 44.88 |
| Environmental score | 3.73 |
| Environmental score percentile | 2 |
| Social score | 14.34 |
| Social score percentile | 2 |
| Governance score | 10.32 |
| Governance score percentile | 2 |
| Level of controversy | 2 |
Dividend payout ratio: 51.41% of net profits
Recently Cochlear has paid out, on average, around 51.41% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.26% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Cochlear shareholders could enjoy a 1.26% return on their shares, in the form of dividend payments. In Cochlear's case, that would currently equate to about A$2.55 per share.
Cochlear's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 22 September 2021 (the "ex-dividend date").
Over the last 12 months, Cochlear's shares have ranged in value from as little as $174.6841 up to $256.2311. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Cochlear's is 0.3472. This would suggest that Cochlear's shares are less volatile than average (for this exchange).
Cochlear Limited provides implantable hearing solutions for adults and children worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. The company was founded in 1981 and is headquartered in Sydney, Australia.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Shares in the wealth management giant have been largely stable in the last 6 months.
Everything we know about the Judo Capital Holdings IPO, plus information on how to buy in.
Everything we know about the Alloggio Group IPO, plus information on how to buy in.
Everything we know about the Larvotto Resources IPO, plus information on how to buy in.
Everything we know about the Vulcan Steel IPO, plus information on how to buy in.
Everything we know about the Artrya IPO, plus information on how to buy in.
Everything we know about the 8 Au IPO, plus information on how to buy in.
Everything we know about the Radiopharm Theranostics IPO, plus information on how to buy in.
The online retailer’s shares have lost more than half their value in the last 12 months.
